United Therapeutics Corp banner

United Therapeutics Corp
SWB:UTH

Watchlist Manager
United Therapeutics Corp Logo
United Therapeutics Corp
SWB:UTH
Watchlist
Price: 466.1 EUR -4.33% Market Closed
Market Cap: €13.2B

Wall St Price Targets

UTH Price Targets Summary
United Therapeutics Corp

Wall Street analysts forecast UTH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for UTH is 580.09 EUR with a low forecast of 451.05 EUR and a high forecast of 681.56 EUR.

Lowest Forecast
Price Target
451.05 EUR
3% Downside
Average Forecast
Price Target
580.09 EUR
24% Upside
Highest Forecast
Price Target
681.56 EUR
46% Upside
United Therapeutics Corp Competitors:
Price Targets
SMCP
SMCP SA
72% Upside
WLFC
Willis Lease Finance Corp
4% Upside

Revenue
Forecast

10% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
10% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 10%. The projected CAGR for the next 8 years is 13%.

Gross Profit
Forecast

10% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
10% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 10%. The projected CAGR for the next 6 years is 15%.

Operating Income
Forecast

10% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
10% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 10%. The projected CAGR for the next 8 years is 14%.

Pre-Tax Income
Forecast

11% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
11% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 11%. The projected CAGR for the next 3 years is 11%.

Net Income
Forecast

12% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss
12% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 12%. The projected CAGR for the next 8 years is 11%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is UTH's stock price target?
Price Target
580.09 EUR

According to Wall Street analysts, the average 1-year price target for UTH is 580.09 EUR with a low forecast of 451.05 EUR and a high forecast of 681.56 EUR.

What is the Revenue forecast for United Therapeutics Corp?
Projected CAGR
13%

Over the last 13 years, the compound annual growth rate for Revenue has been 10%. The projected CAGR for the next 8 years is 13%.

What is the Gross Profit forecast for United Therapeutics Corp?
Projected CAGR
15%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 10%. The projected CAGR for the next 6 years is 15%.

What is the Operating Income forecast for United Therapeutics Corp?
Projected CAGR
14%

Over the last 13 years, the compound annual growth rate for Operating Income has been 10%. The projected CAGR for the next 8 years is 14%.

What is the Pre-Tax Income forecast for United Therapeutics Corp?
Projected CAGR
11%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 11%. The projected CAGR for the next 3 years is 11%.

What is the Net Income forecast for United Therapeutics Corp?
Projected CAGR
11%

Over the last 13 years, the compound annual growth rate for Net Income has been 12%. The projected CAGR for the next 8 years is 11%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett